EVALUATION OF THE PROTECTIVE EFFICACY OF HIV-1 PROTEASE INHIBITORS AGAINST ENTEROVIRUS 71 INFECTION IN VITRO
MetadataShow full item record
Enterovirus associated hand, foot and mouth disease continues to be a prominent public health issue despite the numerous vaccine trials and drug development attempts. The lack of a specific and protective antiviral drug has made disease management extremely challenging and gravely underscores the need for effective therapy options. Nelfinavir, belonging to the HIV-1 protease inhibitors, was found to have significant antiviral activity compared to other HIV-1 protease inhibitors. With a low cytotoxicity and high inhibitory action against both the BrCr and H strain of EV71, nelfinavir exhibited potential broad spectrum antiviral properties. Additionally, its ability to impede the virus irrespective of the stage of the infection makes it a more promising therapeutic option. The data strongly support the potential usefulness of nelfinavir as a broad spectrum antiviral drug with significant protective efficacy against EV71 infection in vitro.